What topics does this cannabis study cover?

This study covers research on: Pain, Inflammation, Endocannabinoid.

Where was this research published?

Published in Reproductive sciences (Thousand Oaks, Calif.) on September 15, 2026.

Review finds cannabinoid mechanisms may target endometriosis pain

Q: What did this Review find?

The review integrates *in vitro*, animal-model, and human evidence on the *endocannabinoid system* in endometriosis-associated pain; it is **not a clinical trial** and provides no new clinical efficacy results.

The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications.

Reproductive sciences (Thousand Oaks, Calif.) • September 15, 2026 • Review • Highly Relevant

🤖

AI Summary

This review examines whether the endocannabinoid system could help explain and address pain associated with endometriosis, a chronic disorder affecting approximately 10% of reproductive-age women. It integrates evidence from in vitro studies, animal models, and human research, while noting that people with endometriosis increasingly use cannabis to manage symptoms. The review is not a clinical trial and reports no new participant group, treatment duration, or quantitative treatment outcomes.

Across laboratory and animal models, cannabinoids appear to influence three processes involved in endometriosis-associated pain: nociceptive signaling, inflammation, and the growth of endometriotic lesions. The reviewed evidence suggests effects on cannabinoid and non-cannabinoid receptors, reduced inflammatory signaling involving cytokines and immune cells, and antiproliferative activity in endometriosis models. The authors conclude that the endocannabinoid system is a promising therapeutic target, but the abstract’s most consequential limitation is that these findings do not establish safety or effectiveness in people; clinical trials are still needed. This is an abstract-based summary and does not assess the full text.

💡 Key Findings

The review integrates in vitro, animal-model, and human evidence on the endocannabinoid system in endometriosis-associated pain; it is not a clinical trial and provides no new clinical efficacy results.

High

95%

In laboratory and animal models, cannabinoids appear to act on three pain-related processes: inflammation, nociceptive signaling, and lesion proliferation.

High

80%

The reviewed evidence indicates that cannabinoids may reduce inflammatory signaling involving cytokines, mast cells, and peritoneal macrophages, while also suppressing pain sensitization.

Good

75%

Antiproliferative effects have been reported in endometriosis models, but clinical trials are needed to determine safety and effectiveness in people.

High

95%

📄 Original Abstract

Endometriosis is a chronic gynecological disorder affecting approximately 10% of reproductive-age women, characterized by the ectopic growth of endometrial tissue and severe pain, including dysmenorrhea, chronic pelvic pain, dyspareunia, dysuria, and dyschezia. Current treatments are limited in efficacy and associated with significant side effects, underscoring the urgent need for novel therapeutic strategies. The endocannabinoid system (ECS) has emerged as a promising therapeutic target, given its well-established roles in pain modulation, inflammation, and immune regulation. Epidemiological evidence demonstrates that women with endometriosis increasingly use cannabis for symptom self-management, yet the underlying mechanisms remain poorly characterized. This review integrates preclinical and human evidence to comprehensively evaluate the mechanistic basis of cannabinoid efficacy in endometriosis-associated pain. Evidence from in vitro studies and animal models indicates that cannabinoids target three main mechanisms of endometriosis-associated pain, including inflammation, nociceptive signaling, and lesion proliferation. Cannabinoids suppress pain signaling and sensitization by interacting with cannabinoid and non-cannabinoid receptors expressed in endometriotic lesions. Cannabinoids attenuate endometriosis-induced inflammation by inhibiting proinflammatory cytokine signaling and reducing the release of inflammatory mediators by mast cells and peritoneal macrophages. Cannabinoids also exert antiproliferative effects in endometriosis models, thereby suppressing the growth of endometriotic lesions. In conclusion, the ECS is a promising therapeutic target for endometriosis-associated pain, as it regulates nociception, inflammation, and proliferation. These promising findings highlight the potential therapeutic benefits of cannabinoids for endometriosis-associated pain, warranting the need for clinical trials to evaluate the safety and effectiveness of cannabinoid therapies in endometriosis.

Paper Type

📚 Review

Publication

Journal: Reproductive sciences (Thousand Oaks, Calif.)
Published: September 15, 2026
PMID: 42745018
DOI: 10.1007/s43032-026-02201-9

Authors (5)

Alexandra M Stone Wayne State University School of Medicine, Detroit, MI, USA.
Vanessa L Veltre Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Olivia G Camp Department of Obstetrics and Gynecology, The C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, 275 E. Hancock, Detroit, MI, 48201, USA.
Mia M Biernat Department of Obstetrics and Gynecology, The C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, 275 E. Hancock, Detroit, MI, 48201, USA.
Husam M Abu-Soud Department of Obstetrics and Gynecology, The C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, 275 E. Hancock, Detroit, MI, 48201, USA. habusoud@med.wayne.edu.